| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 08/25/2009 | US7579317 S-sulfonated; for use in oral supplement to cause reduction in oxidative stress, promoting skin health and antiinflammatory effect |
| 08/25/2009 | US7579316 Compositions and methods to modulate an immune response to an immunogenic therapeutic agent |
| 08/25/2009 | US7579315 Casein peptides for alleviating or preventing aging of skin |
| 08/25/2009 | US7579313 Transglutaminase inhibitors and methods of use thereof |
| 08/25/2009 | US7579169 producing a mutant HH polypeptide by transforming isolated host cells with a vector capable of expressing the polypeptide from the nucleic acid sequence; diagnosis, prenatal screening and diagnosis, and therapies of blood disorders |
| 08/25/2009 | US7579168 Human Dickkopf-related nucleic acid molecules |
| 08/25/2009 | US7579166 lysosomal enzyme having a mannose-6-phosphate-containing acidic sugar chain; a labeling marker for transporting into lysosomes; used as a drug effective in treatment of human lysosomal enzyme deficiencies |
| 08/25/2009 | US7579160 Cervical Cancer; Using monoclonal antibody comprising immunostimulant domains to diagnose and treat cell proliferative disorders; binding; lung tumor polypeptides, immunogenic portions, polynucleotides that encode such polypeptides, antigen presenting , T cells that are specific; |
| 08/25/2009 | US7579141 Method of in vitro diagnosis which discriminates between exposure of a subject to Mycobacterium tuberculosis and vaccination with Bacille Calmette Guerin strain of Mycobacterium bovis, method comprising testing for presence of CD4 T lymphocytes that respond to MTBN4 |
| 08/25/2009 | US7579026 A combination of Bacopa monniera extract, milk thistle extract, ashwagandha powder, green tea extract, and turmeric extract increases the enzyme activity level of superoxide dismutase and catalase and decreases the plasma concentration level of thiobarbituric acid reactive chemical species |
| 08/25/2009 | US7579010 Botulinum toxin pharmaceutical compositions with a recombinant human serum albumin |
| 08/25/2009 | US7579006 Method of treating immune pathologies with low dose estrogen |
| 08/25/2009 | US7579004 diagnosing measles virus infection or immunity to measles virus in a human patient, by analyzing the sample from patients for the presence of the peptides or antibodies to the peptide |
| 08/25/2009 | US7579003 HBsAg-BCG combined vaccine for intracutaneous injection and preparation method thereof |
| 08/25/2009 | US7579001 Antagonists of TWEAK and of TWEAK receptor and their use to treat immunological disorders |
| 08/25/2009 | US7578998 Chimeric cytokine of IL-7 and beta-chain of HGF and methods of use |
| 08/25/2009 | CA2634663C Novel albumin-free factor viii formulations |
| 08/25/2009 | CA2439078C Composition improving age-related physiological deficits and increasing longevity |
| 08/25/2009 | CA2395539C Soluble interleukin-20 receptor |
| 08/25/2009 | CA2385302C Receptor proteins specifically recognizing bacterial dna |
| 08/25/2009 | CA2372456C Viral infection inhibitor targeting integrase n-terminal domain |
| 08/25/2009 | CA2330329C Cerebrospinal and vascular pharmaceutical composition and process for preparing the same |
| 08/25/2009 | CA2099541C Cyclic adhesion inhibitors |
| 08/25/2009 | CA2088889C Specific antibodies against activated platelets, the preparation thereof and the use thereof in diagnosis and therapy |
| 08/22/2009 | CA2619029A1 New cell technologies |
| 08/20/2009 | WO2009103035A2 Templated open flocs of anisotropic particles for enhanced pulmonary delivery |
| 08/20/2009 | WO2009102966A2 Bmp-7 for use in treating vascular sclerosis |
| 08/20/2009 | WO2009102818A1 Method for reducing the effects of chemotheraphy using flagellin related polypeptides |
| 08/20/2009 | WO2009102715A2 Peptide therapy for ocular herpes infections |
| 08/20/2009 | WO2009102677A1 A nutritionally enhanced therapeutic preventative food supplement and method of making same |
| 08/20/2009 | WO2009102497A2 Genetic regulation of host defense mechanisms by mucosal exposure to natural interferon alpha species |
| 08/20/2009 | WO2009102487A2 Gas based wound and tissue therapeutics |
| 08/20/2009 | WO2009102478A1 Inhibition of angiogenesis |
| 08/20/2009 | WO2009102467A2 Devices, formulations, and methods for delivery of multiple beneficial agents |
| 08/20/2009 | WO2009102367A2 Tight junction protein modulators and uses thereof |
| 08/20/2009 | WO2009102357A2 Hiv-1 envelope glycoprotein oligomer and methods of use |
| 08/20/2009 | WO2009102050A1 Intestinal immune system stimulator |
| 08/20/2009 | WO2009102021A1 Treatment of retinal disease by activation of the function of bone marrow-derived stem cell or progenitor cell thereof |
| 08/20/2009 | WO2009102008A1 Low-molecular-weight substance derived from maitake mushroom and having immunostimulating activity and anti-tumor activity |
| 08/20/2009 | WO2009101856A1 Remedy for rheumatoid arthritis |
| 08/20/2009 | WO2009101789A1 Ovarian function-improving agent |
| 08/20/2009 | WO2009101533A1 Treatment of metastatic stage prostate cancer with degarelix |
| 08/20/2009 | WO2009101530A1 Method of treating prostate cancer with the gnrh antagonist degarelix |
| 08/20/2009 | WO2009101467A1 Formulation and method for the prevention and treatment of skeletal manifestation of gaucher's disease |
| 08/20/2009 | WO2009101453A1 Compositions and methods of cure and prophylaxis of hiv/aids and related syndromes |
| 08/20/2009 | WO2009101344A1 Combination of a light ray with a cytochrome c oxydase substrate particularly for improving the appearance of the skin and/or hair |
| 08/20/2009 | WO2009101225A1 Pharmaceutical composition for cancer treatment |
| 08/20/2009 | WO2009101165A1 Composition for absorption through mucous tissue |
| 08/20/2009 | WO2009101146A1 Fish protein hydrolysate having a bone-stimulating and ‑maintaining activity, nutraceutical and pharmacological compositions comprising such a hydrolysate and method for obtaining same |
| 08/20/2009 | WO2009101134A1 Fish protein hydrolysate having a satietogenic activity, nutraceutical and pharmacological compositions comprising such a hydrolysate and method for obtaining same |
| 08/20/2009 | WO2009101012A1 Methods for treating and preventing brain tumors based on bone morphogenetic proteins |
| 08/20/2009 | WO2009100617A1 Polypeptide inhibiting angiogenesis and applicaton thereof |
| 08/20/2009 | WO2009100530A1 Uses of modified elr-cxc chemokine g31p |
| 08/20/2009 | WO2009100505A1 Immunogenic peptides and their use in transplantation |
| 08/20/2009 | WO2009082641A3 Compositions and methods for treating diseases associated with angiogenesis and inflammation |
| 08/20/2009 | WO2009076966A3 Rhoc-based immunotherapy |
| 08/20/2009 | WO2009076580A3 Compositions and methods for the treatment and prevention of cardiovascular diseases |
| 08/20/2009 | WO2009074796A8 Inhibition of scarring using tgf-beta 3 |
| 08/20/2009 | WO2009072831A3 Novel use of flj25416 gene |
| 08/20/2009 | WO2009069983A3 A pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate |
| 08/20/2009 | WO2009067699A3 Methods for providing a system of care for an oxazaphosphorine drug regimen |
| 08/20/2009 | WO2009046872A3 Use of a peptide as a therapeutic agent |
| 08/20/2009 | WO2009034452A4 Compound and device for treating bone and/or cartilage defects |
| 08/20/2009 | WO2009033808A3 Use of a peptide as a therapeutic agent |
| 08/20/2009 | WO2009033789A3 Use of a peptide as a therapeutic agent |
| 08/20/2009 | WO2009033765A3 Use of a peptide as a therapeutic agent |
| 08/20/2009 | WO2009033754A3 Use of a peptide as a therapeutic agent |
| 08/20/2009 | WO2009029342A3 B7-dc variants |
| 08/20/2009 | WO2009002372A3 Prevention and treatment of gram negative, flagellated bacterial infections |
| 08/20/2009 | US20090210954 Genes |
| 08/20/2009 | US20090210949 Method of ameliorating symptom caused by mood disturbance |
| 08/20/2009 | US20090209937 Apparatus and Methods for Treating Epilepsy Using Convection-Enhanced Delivery |
| 08/20/2009 | US20090209747 Method to inhibit cell growth using oligonucleotides |
| 08/20/2009 | US20090209734 Peptidyl prodrugs and linkers and stabilizers useful therefor |
| 08/20/2009 | US20090209732 Secreted and Transmembrane Polypeptides and Nucleic Acids Encoding the Same |
| 08/20/2009 | US20090209635 Topical cromolyn formulations |
| 08/20/2009 | US20090209630 Vectors carrying coding sequences for angiogenic agents such as Del-1or VEGF formulated with poloxamers to improve bioavailability; avoids problems with toxicity inherent to existing delivery technologies; treating ischemia in a muscle, kidney or brain tissue |
| 08/20/2009 | US20090209473 Componds and methods for pormoting angiogenesis |
| 08/20/2009 | US20090209472 Amide and peptide derivatives of dialkylenetriamines and their use as transfection agents |
| 08/20/2009 | US20090209471 Abuse-resistant amphetamine prodrugs |
| 08/20/2009 | US20090209470 T24 antigen for immunodiagnosis of taenia solium cysticercosis |
| 08/20/2009 | US20090209469 Use of Exendins and GLP-1 Receptor Agonists for Altering Lipoprotein Particle Size and Subclass Composition |
| 08/20/2009 | US20090209468 Alpha-neurotoxin proteins with anti-inflammatory properties and uses thereof |
| 08/20/2009 | US20090209467 composition for treatment of a pathologic disorder having as an active ingredient a therapeutically-effective amount of at least one SV40 VP1 65 amino acid truncated mutant deleted in its carboxy terminal arm, designated VP1 Delta C; treatment of immune-related or neurodegenerative disorders |
| 08/20/2009 | US20090209466 Peptides with anti-proliferative activity |
| 08/20/2009 | US20090209465 MCT1 Transporters Expressed in Blood Brain Barrier Cells |
| 08/20/2009 | US20090209464 inhibiting Flavivirus infection by inhibiting the fusion between the virion envelope and a cell membrane; E1 envelope glycoprotein of hepaciviruses and E2 envelope glycoprotein of pestivirus have previously undescribed structures, truncated class II fusion proteins |
| 08/20/2009 | US20090209463 Hgf Precursor Protein Variant and Active Protein Thereof |
| 08/20/2009 | US20090209462 Regulation of function of angiopoietin |
| 08/20/2009 | US20090209461 Modification of feeding behavior |
| 08/20/2009 | US20090209460 Compositions and methods for treating obesity and related metabolic disorders |
| 08/20/2009 | US20090209459 Method of Treating Myasthenia Gravis |
| 08/20/2009 | US20090209458 Cell-penetrating socs polypeptides that inhibit cytokine-induced signaling |
| 08/20/2009 | US20090209457 Treatment of anti-erythropoietin antibody-mediated disorders with synthetic peptide-based epo receptor agonists |
| 08/20/2009 | US20090209456 Compositions and methods for improving facial and body aesthetics |
| 08/20/2009 | US20090209455 Vitreous administration of erythropoietin |
| 08/20/2009 | US20090209454 Method for purifying fsh or a fsh mutant |
| 08/20/2009 | US20090209453 Glycoprotein Hormone Analogs |
| 08/20/2009 | US20090209452 Substantially pure glycopeptide antibiotics ac-98-1; ac-98-2; ac-98-3; ac-98-4 and ac-98-5 |
| 08/20/2009 | US20090209451 Heteroarylaminopyrazole derivatives useful for the treatment of diabetes |